Pharma funding for TB research four times less than government funding

Comments 1

Was less than US$100 million invested in research and development for TB last year? It turns out that this figure is the pharmaceutical industry's share, which is significantly less than what public and philanthropic institutions invest.

Responsible for up to 1.5 million deaths a year, tuberculosis (TB) remains the world’s leading cause of death alongside HIV. Yet private sector funding for research and development into treatment and prevention doesn’t seem to measure up.

That is why a high-level panel of the United Nations met with health advocacy groups in Johannesburg last month to seek ways to finance and incentivise research.

Researcher and activist from South African NGO the Treatment Action Campaign, Marcus Low, attended the meeting. He reportedly later told Business Day that “less than $100 million was invested in research and development for TB last year”.

Up to US$1.3 billion is needed to fill the gap between available funding and required funding for research and development into new medicine against TB, the World Health Organisation noted.

Could money invested in TB research be that low?

Source says he was misquoted

A lab technician opens access to a human sputum sample for a giant rat to detect whether it is infected by tuberculosis at the Eduardo Mondlane university in Maputo, Mozambique, in February 2015. Photo: AFP/ADRIEN BARBIER
A lab technician opens access to a human sputum sample for a giant rat to detect whether it is infected by tuberculosis at the Eduardo Mondlane university in Maputo, Mozambique, in February 2015. Photo: AFP/ADRIEN BARBIER

Low told Africa Check that he had been misquoted. “What I told Tamar [Khan of Business Day] was that industry invested less than US$100 million in TB research and development in the last year,” he said.

“I did not say that total investment in TB research and development (industry plus governments, foundations etcetera) was less than US$100 million.”

To back up his claim, Low cited data from a report by US-based advocacy organisation, Treatment Action Group (no link to Low’s organisation).

The group annually send a survey to public funding agencies, philanthropic organisations, industry groups and select academic and not-for-profit research institutions to gather data on. Survey participants are asked to report disbursements according to one of six research areas: basic science, diagnostics, drugs, vaccines, operational research and infrastructure or unspecified projects.

For its 2015 report, the Treatment Action Group sent their survey to 174 known and potential funders of TB research. 107 surveys were returned, the highest yield in its ten year series, with 20 of the participants from the private sector

The Treatment Action Group data is “the best and (pretty much) only source of data on research funding for TB by the pharmaceutical industry”, Professor Charles Horsburgh who is based at Boston University and whose research focuses on TB, told Africa Check.

The data showed that private sector funding was indeed at approximately US$100 million (US$98,623,440) in 2014, the lowest it has been since 2008.

‘Prospects of a blockbuster drug are low’

Researchers work in the tuberculosis research laboratory of the Pasteur Institute in November 1938 in Paris. Photo: AFP
Researchers work in the tuberculosis research laboratory of the Pasteur Institute in November 1938 in Paris. Photo: AFP

Government funding for TB research was almost four times that of the private sector (US$419 million) and philanthropic funding at US$149 million also exceeded it.

Why is the pharmaceutical industry’s funding for the world’s most deadly infection so low?

“Back in the 1970s it was assumed that TB was a done deal, and all the scientific discoveries that were needed had been made, so science moved on to other issues,” the director of the Center for TB Research at the Johns Hopkins University, Richard Chaisson, told our partner organisation Politifact.

“It turns out that the discoveries of the past were not good enough to result in TB elimination, and the advent of HIV and the emergence of drug-resistant TB made things even worse.”

Chaisson added: “Pharma has had no interest because the disease primarily affects poor people in poor countries, so the prospects of a blockbuster drug are low. The cost of developing drugs for TB are especially high because the large size and long duration of clinical trials.”

Project officer for TB/HIV at the Treatment Action Group and author of their 2015 report, Mike Frick, told Politifact “there’s not a commercial market for TB drug development. It is primarily treated within the public sector, and governments will want to pay the lowest price possible.”


Conclusion: US$674 million was invested in TB research in 2014, not US$100 million

Following a UN meeting in South Africa to incentivise TB research, Business Day incorrectly reported that less than US$100 million had been invested in research and development for TB last year.

The best available data shows that in 2014 US$674 million was spent worldwide, with the bulk coming from the public sector (US$419 million). The reason for this, experts told us, is that the cost of developing TB medicine is high but the expected yield low as governments will want to pay the lowest price possible to treat their citizens.

Note: Africa Check and Politifact receive funding from the Bill and Melinda Gates Foundation which also provides philanthropic funding for TB research and development.


Additional reading

U.S. dominates global TB research spending (in one key way anyhow)

© Copyright Africa Check 2020. Read our republishing guidelines. You may reproduce this piece or content from it for the purpose of reporting and/or discussing news and current events. This is subject to: Crediting Africa Check in the byline, keeping all hyperlinks to the sources used and adding this sentence at the end of your publication: “This report was written by Africa Check, a non-partisan fact-checking organisation. View the original piece on their website", with a link back to this page.

Comment on this report

Comments 1
  1. By d k upadhyaya

    An amazing report. Statistics related to allotment and utilization of funds has been a popular gimmick for some, for years, worlwide. Your organization’s efforts to check and verify the claims based on researches is commendable. Congratulations to Mr Vinayak Bhardwaj for his contribution to raise an issue related to research on a deadly decease to hold someone responsible.
    Don’t you think there is an urgent need of “asiacheck”? Congratulation to help keep democracies transparent.

    Reply Report comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Africa Check encourages frank, open, inclusive discussion of the topics raised on the website. To ensure the discussion meets these aims we have established some simple House Rules for contributions. Any contributions that violate the rules may be removed by the moderator.

Contributions must:

  • Relate to the topic of the report or post
  • Be written mainly in English

Contributions may not:

  • Contain defamatory, obscene, abusive, threatening or harassing language or material;
  • Encourage or constitute conduct which is unlawful;
  • Contain material in respect of which another party holds the rights, where such rights have not be cleared by you;
  • Contain personal information about you or others that might put anyone at risk;
  • Contain unsuitable URLs;
  • Constitute junk mail or unauthorised advertising;
  • Be submitted repeatedly as comments on the same report or post;

By making any contribution you agree that, in addition to these House Rules, you shall be bound by Africa Check's Terms and Conditions of use which can be accessed on the website.


This site uses Akismet to reduce spam. Learn how your comment data is processed.